CoVLP

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Abrilando232 (talk | contribs) at 00:55, 3 April 2021 (→‎References: +cat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

CoVLP
Vaccine description
TargetSARS-CoV-2
Vaccine typeVirus-like particles
Clinical data
Routes of
administration		Intramuscular
Identifiers
DrugBank
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
2024
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Society
virus icon COVID-19 portal

CoVLP is a COVID-19 vaccine candidate developed by Medicago and GlaxoSmithKline (GSK). It is a coronavirus virus-like particle vaccine grown in the Australian weed, Nicotiana benthamiana.[1][2][3]

The Medicago method to manufacture CoVLP is a "molecular farming" technology regarded as rapid, low-cost, and safe.[1][4] It has been proposed specifically for production of COVID-19 vaccines.[5][6]

As of January 2021, the Medicago CoVLP vaccine candidate was in a Phase II-III clinical trial in Canada and the United States, involving 30,918 participants.[7]

Technology

N. benthamiana plant used by Medicago as a "minifactory" for rapid production of coVLP
Nicotiana benthamiana, leaf

CoVLP is an example of a virus-like particle vaccine, consisting of a molecular complex which closely resembles a virus, but is non-infectious because its contains no viral genetic material.[1] It uses recombinant spike proteins derived from SARS-CoV-2.[8][9]

The virus-like particles are produced by creating a bacterium engineered with genes of the virus, then introducing the bacteria into Nicotiana benthamiana plants.[1] The plants take up the bacteria virus-derived generic material, producing in its leaves the virus-like particles, which are then harvested and extracted.[3][10]

In use since the 1990s, the method of using a plant like N. benthamiana has been called "molecular farming" or a "plant-based factory", having vaccine manufacturing advantages of rapid, low-cost production of proteins, large scalability for production, and safety of using plants for pharmaceutical production.[1][4] It has been proposed specifically for production of COVID-19 vaccines.[5][6]

Development

Medicago is developing the COVID-19 vaccine candidate, CoVLP, in collaboration with the governments of Canada and Quebec, and by using an adjuvant manufactured by GlaxoSmithKline (GSK).[8] The GSK adjuvant is intended to enhance the immune response to CoVLP, reducing the amount of antigen required per dose, thereby facilitating mass production of vaccine doses.[11][12]

Clinical research

Phase I

Beginning in August 2020, coVLP was in a Phase I clinical trial at two locations in Quebec to evaluate its safety and immune response.[13]

Phase II-III

In November 2020, Medicago-GSK started a Phase II-III clinical trial for CoVLP, enrolling 30,918 participants in three Canadian provinces and three locations in the United States.[7][9] The Phase II-III trial has an estimated completion date of April 2022.[7]

References

  1. ^ a b c d e LeBlanc, Zacharie; Waterhouse, Peter; Bally, Julia (22 December 2020). "Plant-based vaccines: The way ahead?". Viruses. 13 (1): 5. doi:10.3390/v13010005. ISSN 1999-4915. PMC 7822169. PMID 33375155.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  2. ^ St Philip E, Favaro A, MacLeod M (14 July 2020). "The hunt for a vaccine: Canadian company begins human testing of COVID-19 candidate". CTV News. Retrieved 14 July 2020.
  3. ^ a b Chander V (14 July 2020). "Canada's Medicago begins human trials of plant-based COVID-19 vaccine". National Post. Reuters. Retrieved 14 July 2020.
  4. ^ a b Fischer, Rainer; Buyel, Johannes F. (2020). "Molecular farming – The slope of enlightenment (Review)". Biotechnology Advances. 40: 107519. doi:10.1016/j.biotechadv.2020.107519. ISSN 0734-9750. PMID 31954848.
  5. ^ a b Dhama, Kuldeep; Natesan, Senthilkumar; Iqbal Yatoo, Mohd.; Patel, Shailesh Kumar; Tiwari, Ruchi; Saxena, Shailendra K; Harapan, Harapan (1 December 2020). "Plant-based vaccines and antibodies to combat COVID-19: current status and prospects (Review)". Human Vaccines and Immunotherapeutics. 16 (12): 2913–2920. doi:10.1080/21645515.2020.1842034. ISSN 2164-5515. PMC 7754927. PMID 33270484.
  6. ^ a b Hannah Balfour (15 April 2020). "Plant bio-factories contributing to the COVID-19 fight". Drug Target Review. Retrieved 30 January 2021.
  7. ^ a b c Clinical trial number NCT04636697 for "Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults" at ClinicalTrials.gov
  8. ^ a b "GSK partners with Medicago to develop plant-based Covid-19 vaccine". Pharmaceutical Technology. 8 July 2020. Retrieved 3 August 2020.
  9. ^ a b "Medicago and GSK start of Phase II/III clinical trials of adjuvanted COVID-19 vaccine candidate". Drug Discovery World. 13 November 2020. Retrieved 29 November 2020.
  10. ^ "VLP technologies and production platform". Medicago. Retrieved 30 January 2021.
  11. ^ Chung, Jee Young; Thone, Melissa N.; Kwon, Young Jik (2021). "COVID-19 vaccines: The status and perspectives in delivery points of view". Advanced Drug Delivery Reviews. 170: 1–25. doi:10.1016/j.addr.2020.12.011. ISSN 0169-409X. PMC 7759095. PMID 33359141.
  12. ^ Lucy Parsons (8 July 2020). "GSK signs deal with Medicago for COVID-19 vaccine". PMLive. Retrieved 30 January 2021.
  13. ^ Clinical trial number NCT04450004 for "Safety, Tolerability and Immunogenicity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years" at ClinicalTrials.gov
Scholia has a profile for Medicago Inc. COVID-19 vaccine candidate (Q97154243).
Retrieved from "https://en.wikipedia.org/w/index.php?title=CoVLP&oldid=1015703120"